Robert Hofmeister

Biography
Dr. Hofmeister joined CREATE Medicines as CSO in February 2024. Previously, he was the CSO at Resonance Medicine, where he drove the development of their R&D strategy. Prior to Resonance, he served as CSO at TCR2 Therapeutics, where he started as employee number one and was instrumental in building and leading R&D, driving the development of their TRuC-T cell platform from concept to first-cleared IND (TC-210). Dr. Hofmeister also held various roles at EMD Serono, where he was involved in the development of now-approved Bavencio (avelumab) and building the company’s immuno-oncology platform. He started his career at Micromet AG, now Amgen Research Munich, where he helped shape the development of BLINCYTO® (blinatumomab), the first FDA-approved bispecific antibody for the treatment of refractory ALL. Dr. Hofmeister received his PhD from the University of Regensburg in Germany, where he studied the signaling of interleukin-1. He was a postdoctoral fellow at the National Cancer Institute.

---

Talk
In Vivo CAR Therapy: Immune Reprogramming Directly in Patients
CREATE Medicines has developed an in vivo CAR platform that selectively programs T cells, NK cells, and myeloid cells directly in patients using mRNA and a targeted LNP delivery system. By eliminating complicated ex vivo cell manufacturing and patient conditioning, this approach enables scalable, off-the-shelf immunotherapies for broader patient access.

Emerging Therapeutics Showcase:
CREATE Medicines
CREATE Medicines is a clinical-stage biotech pioneering in vivo CAR therapy. Its proprietary mRNA-LNP platform directly programs immune cells inside the body to deliver scalable, repeat-dose, off-the-shelf immunotherapies. With proven human validation, CREATE is advancing a pipeline of in vivo CAR therapies to transform outcomes in cancer and autoimmunity.